Market access & pricing guidance in rare diseases & ATMP’s

Over the years, we have built up particular expertise in market access and pricing for products in rare diseases.

Bringing new treatments on the market for rare diseases poses particular challenges.  The evidence requirements are typically lower than for ‘regular’ treatments, and clients’ price expectations are usually (very) high.  We see this landscape evolving rapidly, as issues like affordability become more prominent on payers’ agendas.  Thanks to a continued finger on the pulse with our stakeholders, we remain on top of recent trends and can work with our clients how to apply this to their drug development.